Lung Cancer

Recent approval of immunotherapy in the first-line setting for treatment of patients with locally advanced and metastatic non–small cell lung cancer without driver mutations represents changes in care.

H. Jack West, MD, a thoracic oncologist of Swedish Cancer Institute at Swedish Medical Center, discusses the emerging agent lurbinectedin in the small cell lung cancer (SCLC) landscape.

Marina Chiara Garassino, MD, medical consultant in the Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses the PACIFIC study for patients with non–small cell lung cancer (NSCLC).

Benjamin Besse, MD, Institut Gustave Roussy, Villejuif, Paris Sud University, discusses the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) for patients with non

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses the FLAURA trial in patients with EGFR-mutant non–small cell lung cancer.

The FDA approved the first biosimilar for the treatment of cancer. ABP-215 (bevacizumab-awwb; Mvasi), a biosimilar for bevacizumab (Avastin), is indicated for the treatment of colorectal, lung, brain, kidney, and cervical cancers in adult patients.

Although anti-PD-1/PD-L1 immunotherapy has greatly improved the treatment of patients with non–small cell lung cancer and is generally well-tolerated, the therapy backfires in a newly defined subset of patients who experience accelerated tumor growth indicative of hyperprogressive disease.

H. Jack West, MD, thoracic oncologist, Swedish Cancer Institute of Swedish Medical Center, discusses the significance of the PACIFIC trial in patients with non

Suresh S. Ramalingam, MD, deputy director, Winship Cancer Institute of Emory University, discusses the phase III results of the FLAURA trial, which explored osimertinib (Tagrisso) in the frontline setting for patients with EGFR-mutant non-small cell lung cancer (NSCLC).

Solange Peters, MD, PhD, head of the Thoracic Malignancies Program in the Department of Oncology at the University of Lausanne in Switzerland, discusses the FLAURA trial for patients with EGFR-mutated non

Frontline treatment with the combination of dabrafenib and trametinib showed promising clinical efficacy for patients with BRAF-mutant metastatic non–small cell lung cancer.

Expanding surveillance after surgery for early-stage non–small cell lung cancer from chest x-ray to follow-up with PET-CT scan did not improve overall survival.

Nab-paclitaxel (Abraxane) monotherapy has efficacy in patients with pretreated advanced nonsquamous non-small cell lung cancer that is not improved by the addition of CC-486.

A liquid biopsy that measures tumor mutational burden showed promise as an aid for predicting benefit in patients with non-small cell lung cancer treated with a checkpoint inhibitor.

Continuous treatment with nivolumab until disease progression was associated with superior progression-free survival compared with a 1-year fixed duration treatment for patients with previously treated advanced non-small cell lung cancer.

The PD-L1 inhibitor durvalumab improved median progression-free survival by 11.2 months compared with placebo for patients with locally advanced, unresectable stage III lung cancer who had not progressed following chemoradiotherapy.

Frontline osimertinib improved median progression-free survival by 18.9 months, representing a 54% reduction in the risk of progression or death compared with standard therapy for patients with EGFR-mutant non–small cell lung caner.

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses the differences between antiangiogenic agents in lung cancer.

Treatment with alectinib (Alecensa) demonstrated promising efficacy for patients with ALK-translocated non–small cell lung cancer with central nervous system metastases in both the first- and second-line setting.

David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, treasurer, International Association for the Study of Lung Cancer, discusses PD-L1 as a biomarker in lung cancer.

Paul A. Bunn Jr, MD, distinguished professor, Division of Medical Oncology/University of Colorado, James Dudley Chair in Lung Cancer Research, University of Colorado Denver, 2014 Giant of Cancer Care in Lung Cancer, discusses the response of immunotherapy in patients with lung cancer.

Icotinib (Conmana) was associated with a 3.3-month increase in median progression-free survival compared with chemotherapy in patients with stage IIIB/IV non–small cell lung cancer.

Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, chair, Department of Medicine, University of Chicago Medicine, discusses the standard of care for patients with stage III non

Jonathan Riess, MD, assistant professor of medicine, Division of Hematology and Oncology, UC Davis Comprehensive Cancer Center, discusses the long-term benefit with immunotherapy for patients with lung cancer.

Anne Chiang, MD, PhD, professor and thoracic oncologist at Yale Cancer Center, discusses the toxicities with ipilimumab (Yervoy) plus nivolumab (Opdivo) in small cell lung cancer (SCLC).